The Roche lupus treatment Gazyva has been accepted for regulatory review by the US Food and Drug Administration, marking a step towards a potential new therapy for systemic lupus erythematosus.
FDA review of Roche lupus treatment Gazyva
Roche confirmed that the FDA has accepted its supplemental Biologics License Application for Gazyva/Gazyvaro (obinutuzumab) in systemic lupus erythematosus (SLE).
The submission is supported by data from the phase III ALLEGORY study, which evaluated the therapy in combination with standard treatment. A regulatory decision is expected by December 2026.
Phase III data shows reduced disease activity
The ALLEGORY trial demonstrated improved outcomes in people receiving Gazyva alongside standard therapy compared with placebo. At 52 weeks, 76.7% of patients achieved a clinically meaningful improvement in disease activity, compared with 53.5% in the control group.
In addition, the study reported reductions in disease flares and higher remission rates. Safety findings were consistent with the therapy’s established profile, with no new signals identified.
Potential impact on systemic lupus erythematosus treatment
Systemic lupus erythematosus is a chronic autoimmune disease affecting more than three million people worldwide. It can involve multiple organ systems and may lead to long-term complications, including kidney damage.
If approved, Gazyva/Gazyvaro could become the first anti-CD20 therapy specifically targeting B cells in SLE, offering a new approach to disease management.
Growing focus on targeted immunology therapies
The application reflects broader efforts to develop targeted treatments for immune-mediated diseases. Roche is also evaluating Gazyva/Gazyvaro across related conditions, including lupus nephritis and other kidney disorders.
Further details are available via the Roche website. Related coverage can be found in the Pharmaceuticals section.
